Valeant Pharmaceuticals: Worth At Least $30
https://seekingalpha.com/article/4175725-valeant-pharmaceuticals-worth-least-30?source=feed_sector_healthcare
May 21, 2018 - Valeant reported organic growth at both B+L and Salix.Company beat analyst expectations.Strong leadership is one of three positive catalysts that will drive stock higher to $30.VRX stock re-added to t
0
MeiraGTx Aims For $86 Million U.S. IPO
https://seekingalpha.com/article/4175408-meiragtx-aims-86-million-u-s-ipo?source=feed_tag_ipo_analysis
May 18, 2018 - MeiraGTx has filed to raise $86.25 million from the sale of its common stock in an IPO.The firm is developing genetic treatment candidates primarily for inherited eye conditions.MGTX is well into Phas
0
Regeneron Unknown: Eylea Future Competition Effects
https://seekingalpha.com/article/4175167-regeneron-unknown-eylea-future-competition-effects?source=feed_sector_healthcare
May 17, 2018 - Regeneron's future value is highly dependent on Eylea sales.The competition for Eylea is complex and growing.Investors should not assume that Eylea is invulnerable to competition.
0
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
http://www.zacks.com/stock/news/303934/amgens-amgn-repatha-gains-eu-nod-to-include-outcomes-data?cid=CS-ZC-FT-303934
May 17, 2018 - Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
0
I Could Still Be Wrong About Netflix
https://seekingalpha.com/article/4174600-still-wrong-netflix?source=feed_all_articles
May 16, 2018 - At the beginning of the year, I noted my site had been bullish on Netflix for much of last year, and was still bullish on it.Nevertheless, I warned that my site gets calls wrong too, and might end up
0
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
http://www.zacks.com/stock/news/303794/sanofi-eczema-drug-dupixent-succeeds-in-adolescents-study?cid=CS-ZC-FT-303794
May 16, 2018 - Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
0
Scholar Rock Readies $75 Million IPO
https://seekingalpha.com/article/4174198-scholar-rock-readies-75-million-ipo?source=feed_tag_ipo_analysis
May 15, 2018 - Scholar Rock Holding wants to raise $75 million in a U.S. IPO.The company is advancing a number of muscle-wasting disease and cancer treatment candidates into Phase 1 trials.SRRK has a promising relat
0
Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?
http://www.zacks.com/stock/news/303413/will-trumps-surprise-drug-pricing-plan-boost-pharma-stocks?cid=CS-ZC-FT-303413
May 14, 2018 - Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.
0
Get Rich (Safely) With Growth Strategies: 3 To Consider
https://seekingalpha.com/article/4172869-get-rich-safely-growth-strategies-3-consider?source=feed
May 12, 2018 - We mostly write on conservative and/or income-oriented strategies. However, this article focuses on strategies on how to invest in growth stocks.For most people, it is really difficult to recognize th
0
Why The Trade Desk, Noodles & Co., and Regeneron Pharmaceuticals Jumped Today
https://www.fool.com/investing/2018/05/11/why-the-trade-desk-noodles-co-and-regeneron-pharma.aspx?source=iedfolrf0000001
May 11, 2018 - Find out which of these companies had strong earnings.
0
Page 1>
REGN - Nasdaq
http://www.nasdaq.com/symbol/regn
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
REGN - Google Finance
https://www.google.com/finance?q=REGN
Industry related info and international coverage
Summary
News
REGN - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=REGN
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options